

Arbutus Biopharma Corporation and Roivant Sciences Ltd. form Genevant Sciences

Date closed: 4/12/2018

Value: See below

On April 12, 2018, Arbutus Biopharma Corporation (Arbutus), an industry-leading hepatitis B virus (HBV) therapeutic solutions company and Roivant Sciences Ltd. (Roivant) announced that they have entered into an agreement to launch Genevant Sciences (Genevant), a jointly-owned company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics. Under the terms of the agreement, Roivant will contribute \$37.5 million in transaction-related seed capital for Genevant.

BLG acted as Canadian counsel to Arbutus with a team led by Warren Learmonth, that [Stephen Robertson](#) ([Corporate](#)), [Randy Morphy](#) ([Tax](#)) and [Steve Winder](#) ([Employment](#)).

For more information, please contact:

Kate Gifford

Borden Ladner Gervais LLP

KGifford@blg.com

416.350.6540



BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 800 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](https://www.blg.com)

© 2026 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.